MedTrace Logo

Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

NCT04128891 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-08-30

No results posted yet for this study

Summary

To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis, and correlate this to changes in myocardial systolic and diastolic function in HFpEF patients.

Conditions

Interventions

DRUG

Sacubitril-Valsartan

Cardiomagnetic Resonance Imaging

Sponsors & Collaborators

  • Flinders University

    lead OTHER

Principal Investigators

  • Carmine De Pasquale, Assoc Prof · Flinders Medical Centre

  • Majo Joseph, Doctor · Flinders Medical Centre

  • Rajiv Ananthakrishna, Doctor · Flinders Medical Centre

  • Michael Stokes, Doctor · Royal Adelaide Hospital

  • Sean Lal, Doctor · Royal Prince Alfred

  • David Kaye, Professor · Baker Institute/ Alfred Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-02-01
Completion
2024-02-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04128891 on ClinicalTrials.gov